Triple GIP / GLP-1 / glucagon receptor agonist (investigational)
Retatrutide
Investigational triple adding - activity to GIP and GLP-1 signalling for energy expenditure and intake.
Primary Mechanism of Action
Clinical / Scientific
Retatrutide co-activates GIPR, GLP-1R, and the (GCGR). - agonism can increase energy expenditure and hepatic lipid mobilisation in development programmes, while GIP/GLP-1 contribute incretin and satiety effects. It is not broadly labelled in most markets.
Pathway Targets
GIP receptor
Scientific explanation
Incretin agonism.
GLP-1 receptor
Scientific explanation
Satiety / insulinotropic agonism.
Glucagon receptor
Scientific explanation
Energy-expenditure / hepatic metabolic agonism in trials.
Pathway Convergence
Clinical / Scientific
Target → pathway → downstream effect → biological consequence. This is a mechanistic map, not a treatment claim.
Receptor to physiology
Target to downstream effect: GIP receptor → GLP-1 receptor → Glucagon receptor
Mechanistically Relevant Repurposed & Adjunctive Applications
Obesity development programmes
InvestigationalMechanistic rationale
Clinical-stage triple . Mechanism is not a marketing claim of local approval.
Mechanistic Application Matrix
| Biological Target | Mechanism | Potential Relevance | Evidence Level |
|---|---|---|---|
| GIPR/GLP-1R/GCGR | Triple agonism | Intake and energy expenditure | Investigational |
In Plain Language
Retatrutide is an experimental “three-hormone” shot: the two incretins plus - activity, aiming at both eating less and burning more energy.
Compounds Sharing Pathways
Other library compounds whose structured pathway data overlap this ingredient. Shared pathways are not combination recommendations.
Mechanistic information is provided for scientific and educational purposes. Discussion of biological pathways or investigational applications does not establish clinical efficacy or constitute individualized medical advice.